This Article Full Text Full Text (PDF) Supplementary Data Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Buck, E. Articles by Ji, Q.-S. Search for Related Content PubMed PubMed Citation Articles by Buck, E. Articles by Ji, Q.-S.

Feedback Mechanisms Promote Cooperativity for Small Molecule Inhibitors of Epidermal and Insulin-Like Growth Factor Receptors

¹ Translational Research, ² Cancer Biology, and ³ Cancer Chemistry, OSI Pharmaceuticals, Farmingdale, New York and ⁴ In Vivo Pharmacology, OSI Pharmaceuticals, Boulder, Colorado

Requests for reprints: Elizabeth Buck, OSI Pharmaceuticals, 1 Bioscience Park Drive, Farmingdale, NY 11735. Phone: 631-962-0782; Fax: 631-845-5671; E-mail: ebuck{at}osip.com.

Key Words: combination • EGFR • IGF-IR

Epidermal growth factor receptor (EGFR) and insulin-like growth factor-I receptor (IGF-IR) can cooperate to regulate tumor growth and survival, and synergistic growth inhibition has been reported for combined blockade of EGFR and IGF-IR. However, in preclinical models, only a subset of tumors exhibit high sensitivity to this combination, highlighting the potential need for patient selection to optimize clinical efficacy. Herein, we have characterized the molecular basis for cooperative growth inhibition upon dual EGFR and IGF-IR blockade and provide biomarkers that seem to differentiate response. We find for epithelial, but not for mesenchymal-like, tumor cells that Akt is controlled cooperatively by EGFR and IGF-IR. This correlates with synergistic apoptosis and growth inhibition in vitro and growth regression in vivo upon combined blockade of both receptors. We identified two molecular aspects contributing to synergy: (a) inhibition of EGFR or IGF-IR individually promotes activation of the reciprocal receptor; (b) inhibition of EGFR-directed mitogen-activated protein kinase (MAPK) shifts regulation of Akt from EGFR toward IGF-IR. Targeting the MAPK pathway through downstream MAPK/extracellular signal-regulated kinase kinase (MEK) antagonism similarly promoted IGF-driven pAkt and synergism with IGF-IR inhibition. Mechanistically, we find that inhibition of the MAPK pathway circumvents a negative feedback loop imposed on the IGF-IR– insulin receptor substrate 1 (IRS-1) signaling complex, a molecular scenario that parallels the negative feedback loop between mTOR-p70S6K and IRS-1 that mediates rapamycin-directed IGF-IR signaling. Collectively, these data show that resistance to inhibition of MEK, mTOR, and EGFR is associated with enhanced IGF-IR–directed Akt signaling, where all affect feedback loops converging at the level of IRS-1. [Cancer Res 2008;68(20):8322–32]

This article has been cited by other articles:

				N. Jin, T. Jiang, D. M. Rosen, B. D. Nelkin, and D. W. Ball Dual Inhibition of Mitogen-Activated Protein Kinase Kinase and Mammalian Target of Rapamycin in Differentiated and Anaplastic Thyroid Cancer J. Clin. Endocrinol. Metab., October 1, 2009; 94(10): 4107 - 4112. [Abstract] [Full Text] [PDF]

				C. Desbois-Mouthon, A. Baron, M.-J. Blivet-Van Eggelpoel, L. Fartoux, C. Venot, F. Bladt, C. Housset, and O. Rosmorduc Insulin-Like Growth Factor-1 Receptor Inhibition Induces a Resistance Mechanism via the Epidermal Growth Factor Receptor/HER3/AKT Signaling Pathway: Rational Basis for Cotargeting Insulin-Like Growth Factor-1 Receptor and Epidermal Growth Factor Receptor in Hepatocellular Carcinoma Clin. Cancer Res., September 1, 2009; 15(17): 5445 - 5456. [Abstract] [Full Text] [PDF]